Current Status of Biomarkers for Prostate Cancer

International Journal of Molecular Sciences

Vicki M. Velonas²  Henry H. Woo¹  Cristobal G. dos Remedios² 

[1] Sydney Adventist Hospital Clinical School, the University of Sydney, Sydney 2006, Australia; E-Mail:;Bosch Institute, the University of Sydney, Sydney 2006, Australia; E-Mail:

关键词: PSA;    genomics;    antibody microarrays;    diagnostic biomarkers;    genomics;    prostate cancer;    proteomics;   

DOI  :  10.3390/ijms140611034

来源: mdpi

【 摘 要 】

Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rates of false positive results and is not prognostic. Here we review the current status of molecular biomarkers that promise to be prognostic and that might inform individual patient management. It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland